Podcasts about Qiagen

Suzie is a seasoned Business Leader, Board Chair and Advisor, a Scientist who has developed consistent revenue growth strategies for companies in the life science industry including Applied Biosystems, Qiagen and Signant Health. Website: https://suzieharveyconsulting.co.uk LinkedIn: https://www.linkedin.com/in/suzie-harvey-uk/ CallumConnects Micro-Podcast is your daily dose of wholesome leadership inspiration. Hear from many different leaders in just 5 minutes what hurdles they have faced, how they overcame them, and what their key learning is. Be inspired, subscribe, leave a comment, go and change the world!

Send us a textIn this episode of the Life Science Success Podcast my guest is Divya Vijay Pratheek, a seasoned biotechnology leader with over a decade of experience in product and commercial strategy. With a remarkable background spanning roles at QIAGEN, Automata, and Congenica, Divya brings a wealth of expertise in managing global product portfolios and driving innovation at the intersection of biotechnology and product development.00:00 Introduction to Life Science Success Podcast00:43 Meet Divya Vijay Pratheek: Biotechnology Leader01:18 Divya's Journey into Life Sciences01:54 Early Career and Transition to Marketing03:29 Experience at Accenture and Moving to Germany05:32 Joining QIAGEN and Career Growth09:00 Challenges and Overcoming Imposter Syndrome13:39 Transition to Startups and Learning Adaptability19:47 Significant Projects and Accomplishments22:29 Communicating Complex Biotechnology Concepts29:44 Current Focus and Understanding Product Management30:22 A Funny Story About Product Management30:51 Defining Product Management31:24 Product Development and Market Fit32:42 Challenges in Product Management35:29 Balancing Tech and Sales41:51 The Future of Biotechnology48:46 Advice for Aspiring Biotech Professionals53:58 Inspiration and Concerns58:02 Closing Thoughts and Farewell

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Christoph Kapalschinski und Holger Zschäpitz über die miese Lage und die Aussichten auf Besserung nach dem Börsen-Absturz, die Badminton-Rendite und haklige Neo-Broker. Außerdem geht es um Apple, Qiagen, Tesla, Adidas, Nike, Puma, Lululemon, Asics, On Holding, Under Armour, Yonex, Vanguard FTSE All World ETF (WKN: A2PKXG). Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter.[ Hier bei WELT.](https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html.) [Hier] (https://open.spotify.com/playlist/6zxjyJpTMunyYCY6F7vHK1?si=8f6cTnkEQnmSrlMU8Vo6uQ) findest Du die Samstagsfolgen Klassiker-Playlist auf Spotify! Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? [**Hier findest du alle Infos & Rabatte!**](https://linktr.ee/alles_auf_aktien) Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Panik zum Wochenstart: Der DAX rauschte gleich zum Handelsbeginn um 10 % in die Tiefe, das Tagestief lag bei 18.489 Punkten. Zwischenzeitlich kam Hoffnung auf, doch am Ende schloss der Leitindex mit einem deutlichen Minus von 4,1 % bei 19.790 Punkten. Der EuroStoxx50 verlor ebenfalls 4,1 % auf 4.684 Punkte. Der Euro fiel auf 1,0905 US-Dollar. In den USA zeigte der S&P 500 ein nie gesehenes Comeback: Erst -4,7 %, dann +2,9 %. Doch als das Weiße Haus Gerüchte über eine mögliche Zollpause mit China als "Fake News" dementierte, drehte der Markt erneut tief ins Minus. Der Dow Jones verlor sofort weitere 100 Punkte. Qiagen trotzt dem Trend: Dank hoher Nachfrage nach TB-Bluttests legte der Umsatz im Q1 2025 kräftig zu. Auch der Gewinn fiel besser aus als erwartet. Die Prognose wurde angehoben, die Aktie stieg um 2,3 %. Alle Interviews in Langform finden Sie auf boersenradio.de - u.a. mit Hans A. Bernecker, Jochen Stanzl und Thomas Timmermann. Börsenweisheit zum Schluss:"Wenn es an der Börse keine Risiken gäbe, wäre auch nichts zu verdienen." - André Kostolany

Join us as Professor Detlev Riesner, co-founder of Qiagen, reveals the secrets behind building a global biotech powerhouse. Launching Qiagen in 1980s Germany, a time when venture capital was scarce and the path from research to market success was uncharted, Professor Riesner didn't just imagine it—he lived it.

Verfall an den Optionsbörsen treibt Indizes

I had the pleasure of speaking with Heather Javier, a genomic sales specialist at Roche, sales coach, and host of the Transition to Sales podcast. Heather shared her journey from working in translational oncology and stem cell research to transitioning into sales, inspired by her desire to connect, problem-solve, and align her career with her values.Heather's JourneyHeather's career started with a biology degree and a role in translational oncology at Genentech. Her early work involved managing mice for efficacy studies, followed by years in stem cell research, where her hours were dictated by the cells she was culturing.Despite her scientific success, Heather felt a gap between her work and her passion. What energized Heather was networking, problem-solving, and collaboration. Inspired by her own interactions with sales reps, she realized she could make a bigger impact in sales by addressing customer needs more effectively. After a year of networking and revamping her resume, she made the leap into sales, which she describes as the best decision she made for her family and career.NetworkingHeather believes networking is simply about resourcefulness and taking a “heart-centered approach.” During her days at UCSF, she constantly collaborated with statisticians, vendors, and colleagues to troubleshoot experiments. This mindset carried into her sales career, where she emphasized the importance of building authentic connections.Networking isn't just a means to an end; it's about helping others while advancing shared goals. For those who feel intimidated by networking, she suggests shifting your mindset: recognize that people often want to help and are energized by being part of your journey. I couldn't agree more. I have experienced this many times over many years.Transitioning from Science to SalesHeather knows scientists and technical professionals have the skills needed for sales roles—they often don't realize it. Sales, at its core, is about problem-solving, asking the right questions, and connecting solutions to customer needs.Scientists are used to analyzing variables and troubleshooting experiments. In sales, this translates to understanding customer pain points, guiding discussions with targeted questions, and tailoring solutions. Heather highlighted the importance of being prepared, leveraging technical knowledge, and staying resourceful. These are things scientists do regularly.Overcoming Fear and Building Confidence One of the biggest hurdles for those transitioning into sales: building confidence. Her advice? Treat the learning process like you would in a lab. Just as scientists train to operate new equipment, aspiring sales professionals can prepare by studying their business, asking questions, and leaning on mentors.Heather shared her own experience of transitioning into sales at QIAGEN, where she won President's Club in her first year. Her success came from applying her scientific mindset to sales—studying customer personas, analyzing data, and proactively creating business plans. Confidence, she emphasized, comes from preparation and a willingness to learn. In other words: be curious and do your homework. Isn't that what we've been doing our whole life?Not subscribed? Let's fix that, shall we? Subscribe for free to receive new posts by email. (No Spam. I promise.)Bridging the Gap Between Sales and MarketingHeather isn't the first to point out that sales and marketing often operate in silos, which can lead to missed opportunities. She urged marketers to view sales teams as their “customers” and collaborate closely to create materials that resonate with what sales reps are hearing in the field.Here is an idea she shared that I can get behind. Cultivate a sense of culture and community at conferences. Instead of relying solely on product demonstrations, create experiences that reflect the company's values and culture, helping to attract ideal clients and foster stronger connections.Connecting the Dots: Relationship Building in SalesHeather frequently mentions the idea of connecting the dots. She described her role as a connector—both within her company and with her customers. Building trust and relationships is essential, whether it's with decision-makers at a customer's organization or with internal teams like R&D and technical specialists.She stressed the importance of identifying “coaches” within customer organizations—people who advocate for your product or service and help you navigate the decision-making process. Heather's approach to connecting the dots involves bringing people together, asking thoughtful questions, seeking feedback, and leveraging internal and external resources to solve problems collaboratively.Sales Coaching for StartupsIn addition to her sales role, Heather is developing a program to coach startups on building their own sales strategies. Hiring a dedicated sales team can be expensive. Heather's vision is to help technical teams get comfortable with the fundamentals of sales. Her coaching focuses on skills like prospecting, navigating customer personas, and moving opportunities through the sales funnel, all while staying true to the company's culture and mission.For startups with a strong sense of purpose, Heather's coaching aims to channel that passion into effective customer connections.Empowering Women in SalesHeather's podcast, Transition to Sales, is geared toward women—particularly mothers—looking to move into sales roles from technical backgrounds. She provides actionable advice, free resources like resume guides, and insights into building confidence in sales. Heather's mission is to create representation in an industry that is still predominantly male, showing women that their skills and perspectives are invaluable in sales.Heather's story is a testament to the power of aligning your career with your values and passions. Her journey from the lab to sales demonstrates how scientific skills can translate into successful sales strategies, and her heart-centered approach serves as an inspiring model for others considering a similar transition.For anyone interested in learning more, be sure to check out her podcast and connect with her on LinkedIn.Your deepest insights are your best branding. I'd love to help you share them. Chat with me about custom content for your life science brand. Or visit my website. This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit cclifescience.substack.com

Der DAX schloss mit einem Minus von 0,4 % bei 20.133 Punkten, nachdem er vormittags auf 20.025 Punkte gefallen war. Der EUROSTOXX50 verlor 0,5 % und notierte bei 4954 Zählern. An der Wall Street zeigte der Nasdaq-Composite zum Start mit minus 1,4 % deutliche Schwäche. Der Euro fiel auf 1,0211 US-Dollar. Im DAX waren Autowerte gefragt: Porsche AG legte 2,8 % zu, Mercedes-Benz und Volkswagen bis zu 1,5 %. Qiagen gewann 1,5 %, nachdem das Unternehmen einen Aktienrückkauf von bis zu 300 Mio. US-Dollar angekündigt hatte. Moderna senkte die Umsatzprognose für 2025, was die Aktie um über 20 % einbrechen ließ. Eli Lilly plant eine Übernahme im Bereich Krebstherapien für bis zu 2,5 Mrd. US-Dollar. Redcare verlor 7,6 % auf 115,30 Euro, während Lufthansa den Einstieg bei ITA Airways mit 325 Mio. Euro vorantreibt. Mehr Details und Einschätzungen im Börsenradio to go Podcast. Börsenweisheit: "Es gibt keine Gewinne ohne Risiken und keine Gelegenheiten ohne Herausforderungen."- Benjamin Graham.

Thu, 21 Nov 2024 09:55:00 +0000 https://boersenradio-marktbericht.podigee.io/1584-borsenradio-live-blick-do-21-11-24-dax-unter-19-000-big-short-bei-siemens-energy-symrise-optimistischer-gold-steigt-stark 4422e7b8ec8af557f5d8a89499bd6bb5 Christian Drastil mit dem Live-Blick aus dem Studio des Börsenradio-Partners audio-cd.at in Wien wieder intraday mit Kurslisten, Statistiken und News aus Frankfurt und Wien. Es ist der Podcast, der das Gefühl für den DAX bringt, es ist Donnerstag, der 21. November 2024 und so sieht es im Frühgeschäft aus. - DAX im Frühgeschäft leichter, aktuell unter 19000 - Qiagen im Frühgeschäft gesucht - Porsche Vzg. im Frühgeschäft schwächer - News-Roundup der Baader Bank: BASF, Infineon, Siemens Energy, Symrise, VW - Serien: Merck (5-) - ATX fester - Pierer Mobility gesucht - 1 kg Gold kostet 81.500 Euro, mitgeteilt von Gold & Co. - All-time-High-Jingle: https://audio-cd.at/page/playlist/5438  - Wiener Börse Party: https://www.audio-cd.at/wienerboerseparty Bleiben Sie informiert und hören Sie jetzt rein für tiefere Einblicke und Analysen unter: www.boersenradio.de . Mehr Österreich-Content von Christian unter www.audio-cd.at/wienerboerseplausch bzw. www.audio-cd.at/spotify . Feedback? christian.drastil@boerse-social.com Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 1584 full no

Unser Partner Scalable Capital ist der einzige Broker, den du brauchst. Inklusive Trading-Flatrate, Zinsen und Portfolio-Analysen. Alle weiteren Infos gibt's hier: scalable.capital/oaws. Aktien + Whatsapp = Hier anmelden. Lieber als Newsletter? Geht auch. Das Buch zum Podcast? Jetzt lesen. Siemens Energy schlägt NVIDIA. Just Eat Takeaway, VW, Rivian, BioNTech, Klarna machen beim Deal-Tag mit. Bei Knaus Tabbert und RTL ist Untergangsstimmung. Bei Spotify und Auto1 ist Gewinn-Wachstums-Stimmung. Investoren lieben gut planbare und wiederkehrende Umsätze. Meistens suchen sie dafür nach Softwarefirmen mit Abo-Modell. Der Abo-Champion im DAX ist aber nicht SAP. Sondern Qiagen (WKN: A400D5). Trump gewinnt Wahl. Bitcoin steigt. Aber was jetzt? Kann der Hype anhalten? Was hat Trump vor? Wir klären auf. Diesen Podcast vom 14.11.2024, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung.

Thu, 07 Nov 2024 12:41:00 +0000 https://jungeanleger.podigee.io/1817-wiener-borse-party-776-atx-probiert-auch-heute-plus-zahlenleger-brav-schade-um-christian-lindner-nicht-um-die-nachbarampel 3b7f30a1dca4ae47eabac7f8a3362d2d Die Wiener Börse Party ist ein Podcastprojekt für Audio-CD.at von Christian Drastil Comm..Unter dem Motto „Market & Me“ berichtet Christian Drastil über das Tagesgeschehen an der Wiener Börse. Inhalte der Folge #776: - ATX heute mit erneutem Versuch des Fester-Seins - Zahlen von Semperit, Verbund, Addiko, Valneva - Nicht schade um die Ampel, schade um Christian Lindner - News zu Palfinger, Immofinanz, Uniqa, Kapsch TrafficCom - neu bei Kapitalmarkt-stimme: Addiko Bank, Wiener Börse - weiter gehts im Podcast Links: - Börsenradio Live-Blick 7/11: DAX startet fester, Good News bei Qiagen, Daimler Truck, Heidelberg und in Wien Verbund, Addiko . Hören: https://open.spotify.com/episode/2cTprR7bDAQZtm5WCTUnJT  - kapitalmarkt-stimme-Jingle-Mann Steve Kalen: https://open.spotify.com/intl-de/artist/6uemLvflstP1ZerGCdJ7YU - die Börsegeschichte-Aspekte sind presented by Petrus Advisers: https://www.petrusadvisers.com - Playlist 30x30 Finanzwissen pur für Österreich auf Spotify: https://open.spotify.com/playlist/3MfSMoCXAJMdQGwjpjgmLm - Stockpicking Österreich: https://www.wikifolio.com/de/at/w/wfdrastil1? ATX aktuell: https://www.wienerborse.at/indizes/aktuelle-indexwerte/preise-mitglieder/??ISIN=AT0000999982&ID_NOTATION=92866&cHash=49b7ab71e783b5ef2864ad3c8a5cdbc1 Theme-Song Infos Dominik Plangger: https://audio-cd.at/page/podcast/6379/ Die 2024er-Folgen vom Wiener Börse Plausch (Co-verantwortlich Script: Christine Petzwinkler) sind präsentiert von Wienerberger, CEO Heimo Scheuch hat sich ebenfalls unter die Podcaster gemischt: https://open.spotify.com/show/5D4Gz8bpAYNAI6tg7H695E  . Risikohinweis: Die hier veröffentlichten Gedanken sind weder als Empfehlung noch als ein Angebot oder eine Aufforderung zum An- oder Verkauf von Finanzinstrumenten zu verstehen und sollen auch nicht so verstanden werden. Sie stellen lediglich die persönliche Meinung der Podcastmacher dar. Der Handel mit Finanzprodukten unterliegt einem Risiko. Sie können Ihr eingesetztes Kapital verlieren. Und: Bewertungen bei Apple (oder auch Spotify) machen mir Freude: http://www.audio-cd.at/spotify http://www.audio-cd.at/apple 1817 full no Christian Drastil Comm.

Thu, 07 Nov 2024 09:40:00 +0000 https://boersenradio-marktbericht.podigee.io/1565-borsenradio-live-blick-do-7-11-24-dax-startet-fester-good-news-bei-qiagen-daimler-truck-heidelberg-und-in-wien-verbund-addiko b04d3d377aa23e9ad6cbb82e7a6aa04d Christian Drastil mit dem Live-Blick aus dem Studio des Börsenradio-Partners audio-cd.at in Wien wieder intraday mit Kurslisten, Statistiken und News aus Frankfurt und Wien. Es ist der Podcast, der das Gefühl für den DAX bringt, es ist Donnerstag, der 7. November 2024 und so sieht es im Frühgeschäft aus. - DAX im Frühgeschäft stärker - Qiagen gesucht - Siemens Energy verliert - News-Roundup der Baader Bank: Airbus, Commerzbank, Daimler Truck, Heidelberg Materials, Munich Re, Qiagen, Rheinmetall, RWE - Serien: VW (5-) - Trump-Streuung: 4 Titel starteten auf Jahreshoch- und gleich 9 auf Low in den Markt - ATX fester - Verbund, Addiko Bank stark - 1 kg Gold kostet 79.400 Euro, mitgeteilt von Gold & Co: goldundco.at - All-time-High-Jingle: https://audio-cd.at/page/playlist/5438  - Wiener Börse Party: https://www.audio-cd.at/wienerboerseparty Bleiben Sie informiert und hören Sie jetzt rein für tiefere Einblicke und Analysen unter: www.boersenradio.de . Mehr Österreich-Content von Christian unter www.audio-cd.at/wienerboerseplausch bzw. www.audio-cd.at/spotify . Feedback? christian.drastil@boerse-social.com Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 1565 full no

What a genuine pleasure to sit with Thierry Bernard, CEO of Qiagen. As I told Thierry, Qiagen is a truly iconic brand for anyone who came up through molecular biology laboratories in the past 30 years. Their products were ubiquitous, and crucial, to the success of our research. In this conversation, Thierry talks about his global vision for precision medicine, and his mantra that we leave no patient behind. Episode 39 links: ⁠⁠⁠⁠⁠TPM E39⁠⁠⁠ for highlights and links from this episode >⁠⁠⁠ Genialis™ krasID Poster at 6th Annual RAS-Targeted Drug Development Summit 2024 ⁠⁠⁠Genialis' Upcoming Events⁠⁠⁠ Genialis on LinkedIn

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Medtronic's chief medical officer of acute care and monitoring has departed for a new role. The FDA has finalized voluntary malfunction summary reporting guidance. Penumbra is laying off 71 people after axing its virtual reality division. Qiagen and AstraZeneca have expanded their companion diagnostic pact. The Association for Molecular Pathology is suing to block an FDA lab test rule. Layoffs in the medical device industry continue to be a trend. Industry news includes the launch of the first over-the-counter glucose monitor, unexpected partnerships in diabetes tech, and pushback on FDA regulation of lab-developed tests.The text discusses various updates in the biopharma industry, including Alnylam's heart drug data sparking debate, Novo building a heart failure case for semaglutide, and a slump in cell and gene therapy investment. The industry is shifting towards more patient-centric commercialization strategies, with companies like Pfizer and Lilly breaking into the direct-to-consumer market. The summer has been a mixed bag for biotech, with market fluctuations and limited IPOs and acquisitions. Alnylam's full study data on its heart drug vutrisiran showed benefits but also raised skepticism. Novo's analysis showed semaglutide's effectiveness in reducing heart failure risk. Additionally, PBM executives are facing fines for alleged perjury in a house hearing defending their business practices.The text discusses the pricing and sales of gene therapies, particularly focusing on Novartis' Zolgensma, which has been the only gene therapy to cross the blockbuster threshold with sales of $1.2 billion in 2021 and $1.4 billion in 2022. While high price tags have not always resulted in significant returns for pharmaceutical companies with gene therapies, Zolgensma has been an exception. Other companies have faced challenges with new gene therapies, such as Biomarin Pharmaceuticals, which recently announced layoffs due to dismal sales of its hemophilia A gene therapy Roctavian.Alnylam Pharmaceuticals has released detailed data on their drug Vutrisiran, showing its benefits in treating a progressive and fatal heart condition known as ATTR cardiomyopathy. The results were published in the New England Journal of Medicine. While the data confirms the therapy's benefit, there are still questions about how exactly Vutrisiran should be used in treating the disease. The study is expected to continue to fuel debate among doctors.The text discusses the recent slump in investment in cell and gene therapy, with fewer venture funding rounds closed by developers in the first six months of 2024. Two companies, Biomarin and Tome Biosciences, are cutting jobs, with over 200 and over 100 layoffs respectively. Biomarin has made changes to its executive team and drug pipeline to refocus resources. Additionally, Bayer has partnered with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. The text also highlights the challenges faced in clinical trials, with nearly 80% failing to meet enrollment goals and schedules. The importance of understanding social determinants of health for research is emphasized.Biopharma Dive's Gene Therapy Weekly provides news and insights on gene therapy for biopharma leaders.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma e Biotech world.Clinical trials often fail to meet their enrollment goals and schedules, leading to significant financial losses. A new playbook offers solutions to address common challenges in clinical trial recruitment, including strategies for identifying additional participants, engaging and empowering individuals, and refining protocol criteria. The playbook provides insights on how to rescue trials when misalignment occurs, aiming to help brands in the biopharma industry tell compelling stories, build trust, and drive demand.Penumbra has decided to exit the virtual reality business, resulting in the layoff of 71 employees, as the company shifts its focus back to its core thrombectomy business. Qiagen and AstraZeneca have expanded their companion diagnostic partnership beyond cancer, allowing specialty care providers to perform genotyping during routine clinical examinations. Illumina has received FDA approval for a companion diagnostic cancer test that can identify patients eligible for treatment with specific medications targeting genetic features. Johns Hopkins, CareFirst, and Techstars have launched a healthcare AI accelerator program to support up to 12 startups working on AI tools. Medical sales teams are increasingly investing in training and skills development to adopt a more human-centered approach to sales.Biopharmaceutical company BioMarin has announced its second round of layoffs this year, with 225 employees globally being let go. This comes after changes to the company's C-suite last week and a previous round of 170 job cuts in May. In other news, Novartis is expanding its Sirna therapy Leqvio after successful Phase III study results, while Merck has ended two late-stage studies of Keytruda due to disappointing data. Regeneron is suing Sandoz in federal court to block a biosimilar of its drug Eylea. The pharma industry continues to see changes and challenges, with companies making strategic decisions based on clinical trial results and market conditions.Cognition Therapeutics, a small biotech company, recently announced positive results from a mid-stage Alzheimer's study. However, despite the promising results, the company's share price plummeted, puzzling many. The conflicting narratives surrounding the study highlight the significance of presenting scientific results in a way that reassures investors about the risks involved. The success of clinical trials is crucial for small biotechs in the competitive field of Alzheimer's research. Investor support is essential for advancing treatments for Alzheimer's, as progress cannot be made without adequate funding.The Health and Human Services (HHS) plans to appeal a lawsuit decision regarding online tracking technology. The Northwell-Nuvance merger has been approved by state attorneys general with certain conditions, while McLaren Health Care has restored its network after a ransomware attack. The shortage of mental health providers is being addressed with digital tools, and efforts to combat burnout in healthcare are ongoing.Neurocrine's mixed schizophrenia data disappoint Wall Street despite "positive" results, leading to a 20% slide in shares. The FDA rejection of the first MDMA therapy signals challenges in the psychedelic drug field. Bayer partners with RNA drugmaker Nextrna Therapeutics to develop new cancer therapies. A study suggests that covering Wegovy for heart risk could cost Medicare tens of billions each year.Pfizer has partnered with Flagship's Quotient to utilize genetics in targeting heart and kidney diseases. Moderna is facing tough competition as it tries to determine its next move in the biopharmaceutical industry. Neurocrine Biosciences saw a drop in shares despite meeting the primary endpoint in a mid-stage schizophrenia trial.Lykos Therapeutics faced a setback when the FDA rejected its MDMA therapy for PTSD and laun

Hey guys! Welcome back to the So Cultured Podcast! We're kicking off our brand new series with a bang. This season, we want to expose the science from your favourite tv shows and movies. In episode 1 we will be delving into the science that is the driving force behind The Last of Us. How realistic is the show? Could climate change really affect which creatures the cordyceps fungus infects? Could we really become zombies? Listen in to find out! And don't forget, we always serve every episode with a side of the hottest laboraTEA. This week we have a juicy listener story all about some rumours about her and her PI, can you relate?? We are so excited for you guys to listen to not only this episode, but this entire season, because we had so much fun making it! Please let us know what you thought of the episode in the comments. If you love following our podcast, please do give us a rating and a follow! :) The winner of the season 2 giveaway is @beccajacobs, congratulations! Please dm us on Instagram to claim your prizes! Qiagen's FREE dPCR course- sign up here: https://event.on24.com/wcc/r/4632346/05C98C97B4025F3CBC200FECFB72EBDE/5555107?partnerref=CM_GLS_dPCR_LearnandGrow_0924_OTHERS_Other_podcast_cultured Please remember that this podcast is intended for mature audiences only, as we occasionally delve into subjects that may not be suitable for younger listeners. To learn more about the science: https://www.youtube.com/watch?v=XuKjBIBBAL8 https://www.npr.org/2023/02/17/1157842018/the-science-that-spawned-fungal-fears-in-hbos-the-last-of-us https://screenrant.com/last-us-outbreak-cordyceps-infection-origins-spores-real/#:~:text=The%20origin%20of%20the%20Cordyceps,became%20infected%20in%20South%20America. https://thelastofus.fandom.com/wiki/Cordyceps_brain_infection https://screenrant.com/last-of-us-show-jakarta-infection-outbreak-origin-change/ https://www.youtube.com/watch?v=HBi8ah1ku_s https://edition.cnn.com/2024/04/15/world/cicada-fungus-zombie-scn/index.html   Do you have any questions or wish to collaborate? Feel free to reach out to us at ⁠soculturedpodcast@gmail.com⁠. instagram: ⁠⁠https://www.instagram.com/soculturedpodcast/⁠⁠ twitter/X : ⁠⁠https://twitter.com/SoCulturedPod⁠⁠ youtube: ⁠https://youtube.com/@SoCulturedPodcast⁠ tiktok: ⁠https://www.tiktok.com/@soculturedpodcast

Tue, 06 Aug 2024 11:10:00 +0000 https://boersenradio-marktbericht.podigee.io/1429-borsenradio-live-blick-mo-6-8-24-dax-fester-in-den-dienstag-zalando-top-auch-siemens-energy-rheinmetall-und-in-wien-at-s-stark 10a41e875184d6a06f30586db1646e09 Christian Drastil mit dem Live-Blick aus dem Studio des Börsenradio-Partners audio-cd.at in Wien wieder intraday mit Kurslisten, Statistiken und News aus Frankfurt und Wien. Es ist der Podcast, der das Gefühl für den DAX bringt, es ist Dienstag, der 6. August 2024 und so sieht es im Frühgeschäft aus. - DAX erholt - Zalando führt Gewinnerfeld im Frühgeschäft an - Qiagen schwächer - 6 Titel mit mind. 5 Tagen am Stück im Minus - 8 Titel auf Jahrelosw - News-Roundup der Baader Bank: adidas, Airbus, Bayer, Conti, Zalando - ATX deutlich stärker - AT&S gesucht - 1 kg Gold kostet 70.831 Euro, mitgeteilt von Gold & Co: goldundco.at - All-time-High-Jingle: https://audio-cd.at/page/playlist/5438  - Wiener Börse Party: https://www.audio-cd.at/wienerboerseplausch Bleiben Sie informiert und hören Sie jetzt rein für tiefere Einblicke und Analysen unter: www.boersenradio.de . Mehr Österreich-Content von Christian unter www.audio-cd.at/wienerboerseplausch bzw. www.audio-cd.at/spotify . Feedback? christian.drastil@boerse-social.com Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 1429 full no

Fri, 02 Aug 2024 08:17:00 +0000 https://boersenradio-marktbericht.podigee.io/1425-borsenradio-live-blick-fr-2-8-24-dax-kracht-unter-18-000-intel-sturz-trifft-infineon-wow-krypto-traders-place-baader-gold-high a76d3d73dcf1625d9e563c96beefb592 Christian Drastil mit dem Live-Blick aus dem Studio des Börsenradio-Partners audio-cd.at in Wien wieder intraday mit Kurslisten, Statistiken und News aus Frankfurt und Wien. Es ist der Podcast, der das Gefühl für den DAX bringt, es ist Freitag, der 2. August 2024 und so sieht es im Frühgeschäft aus. - DAX am gestrigen 150. Handelstag 2024 mit dem stärksten Verlust, heute weiter schwach und unter 18.000 - Qiagen gesucht - Intel-Crash zieht Infineon mit - Serien: RWE (davor 11+) gestern gerissen - News-Roundup der Baader Bank: Brenntag - ATX verliert ebenfalls - die zwei D-Partner aus diesem Roadshow-Kreis, Baader Bank und Traders Place, verlängern miteinander und schauen auf Kryptos - High: 1 kg Gold kostet 73.305 Euro, mitgeteilt von Gold &Co: goldundco.at - All-time-High-Jingle: https://audio-cd.at/page/playlist/5438  - Wiener Börse Party: https://www.audio-cd.at/wienerboerseplausch Bleiben Sie informiert und hören Sie jetzt rein für tiefere Einblicke und Analysen unter: www.boersenradio.de . Mehr Österreich-Content von Christian unter www.audio-cd.at/wienerboerseplausch bzw. www.audio-cd.at/spotify . Feedback? christian.drastil@boerse-social.com Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 1425 full no

Thu, 01 Aug 2024 09:25:00 +0000 https://boersenradio-marktbericht.podigee.io/1423-borsenradio-live-blick-do-1-8-24-dax-schwachelt-zu-august-start-mtu-top-bmw-flop-rwe-challenged-beiersdorf-gold-high 38b8234875151e28fcf766527fbafd93 Christian Drastil mit dem Live-Blick aus dem Studio des Börsenradio-Partners audio-cd.at in Wien wieder intraday mit Kurslisten, Statistiken und News aus Frankfurt und Wien. Es ist der Podcast, der das Gefühl für den DAX bringt, es ist Donnerstag, der 1. August 2024 und so sieht es im Frühgeschäft aus. - DAX startet deutlich schwächer in den August - MTU gesucht - BMW unter Druck - Sartorius im Juli top, Siemens Healthineers flop - Serien: RWE (11+), Sartorius (7+), , Rekord 2024 (Beiersdorf 13+) - News-Roundup der Baader Bank: Bayer; BMW, Commerzbank, Daimler Truck, Deutsche Telekom, Merck, Music Re., MTU, Qiagen, Vonovia - ATX verliert ebenfalls, aber weniger als der DAX - ATX vs. DAX vs. ATX TR, MDAX und SDAX - 1 kg Gold kostet 72.794 Euro, mitgeteilt von Gold &Co: goldundco.at - All-time-High-Jingle: https://audio-cd.at/page/playlist/5438  - Wiener Börse Party: https://www.audio-cd.at/wienerboerseplausch Bleiben Sie informiert und hören Sie jetzt rein für tiefere Einblicke und Analysen unter: www.boersenradio.de . Mehr Österreich-Content von Christian unter www.audio-cd.at/wienerboerseplausch bzw. www.audio-cd.at/spotify . Feedback? christian.drastil@boerse-social.com Du möchtest deine Werbung in diesem und vielen anderen Podcasts schalten? Kein Problem!Für deinen Zugang zu zielgerichteter Podcast-Werbung, klicke hier.Audiomarktplatz.de - Geschichten, die bleiben - überall und jederzeit! 1423 full no

In der heutigen Folge von “Alles auf Aktien” sprechen die Finanzjournalisten Daniel Eckert und Nando Sommerfeldt über den nächsten großen Rheinmetall-Deal, Kursfantasie für Zalando und ein seltsames Tesla-Plus. Außerdem geht es um Sartorius und Qiagen, Bechtle, Bitcoin, SAP, Fortnox (WKN: A3DWAB) und Airbus. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge von "Alles auf Aktien" sprechen die Finanzjournalisten Laurin Meyer und Nando Sommerfeldt über Bestechungs-Ärger bei Adidas, zehn Blockbuster-Hoffnungen von Bayer und Warren Buffetts neueste Verkäufe. Außerdem geht es um Apple, Microsoft, Nvidia, Broadcom, Micron Technology, Palantir, Berkshire Hathaway, BYD, Carl Zeiss Meditec, Evotec, Porsche AG, Qiagen, Thermo Fisher und Deutsche Bank. Wir freuen uns an Feedback über aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Der DAX scheint sich in dieser Woche wieder in die richtige Richtung zu bewegen. Gestern notierte er kurzzeitig bereits über der Marke von 18.100 Punkten. Heute peilt der den Sprung über 18.200 Zähler an.

Die erste Zinssenkung der EZB seit einigen Jahren hat die Anleger gestern wenig beeindruckt. Am Ende des Tages ging der deutsche Leitindex dann mit einem Zugewinn von 0,4 Prozent aus dem Handel. Schlusskurs: 18.652 Punkte.

Das Zukunftsprojekt NFT scheint gescheitert. Digitale Kunst ist zumindest für den Moment das gewesen, was Kritiker von Beginn an sagten: Eine Nonsens-Blase. Die Preise für die Blockchain-Token sind um 90 Prozent eingebrochen. Aus Anlegersicht bleibt der Grundgedanke aber weiterhin wertvoll. Börsenreporterin Anne Schwedt erklärt, warum sie davon überzeugt ist.Anschließend ein Update zum Fitnessgeräte-Hersteller Peloton. Gerade wurde eine weitere Entlassungsrunde bekanntgegeben und der für den Neuanfang nach dem Corona-Hoch geholte Chef hat seinen Abgang verkündet. Was Aktionäre jetzt dazu wissen sollten.Im Dax-Update rückt ein Hidden Champion des deutschen Leitindex in den Mittelpunkt: Qiagen. Das Biotech-Unternehmen hat mehr Potenzial, als der erste Blick in die aktuelle Bilanz preisgibt.Zum Schluss wird in der Community Corner wieder eine Frage aus den Reihen der Hörerinnen und Hörer beantwortet. Diesmal geht es um den mRNA-Spezialisten CureVac. Die Aktie hat seit ihrem Hoch rund 95 Prozent an Wert verloren.Die komplette Ausgabe ist Teil der Pioneer-Membership. Wer noch nicht an Bord ist, kann unser gesamtes Portfolio zunächst testen, dafür gibt es hier ein spezielles Angebot.-Und noch ein Hinweis in eigener Sache: Das Podcast-Team von ThePioneer ist mit der Spezialreihe Schattenmächte für den diesjährigen Deutschen Podcast Preis nominiert. Wer gewinnt, bestimmt das Publikum. Wir freuen uns über jede Stimme! Hier geht es zum Voting. ID:{5tNAPhKJAHPlDj46SlXM1i}

Der DAX ist gestern nach anfänglichen Gewinnen ins Minus gerutscht. Am Ende des Tages ging er mit einem Verlust von 0,24 Prozent aus dem Handel.

This week's guest is Joseph Pearson, Global Product Manager of OmicSoft at QIAGEN, a global provider of sample-to-insight solutions that enable customers to gain valuable molecular insights.   During this episode, we dive into OmicSoft, a powerful NGS analysis suite that can quickly explore and compare 500,000 curated omics samples from disease-related studies. Joseph outlines the challenges of acquiring and analysing NGS data sets, how customers can interact with OmicSoft data, and what he thinks of the build versus buy debate when selecting new bioinformatics tools. Data in Biotech is a fortnightly podcast exploring how companies leverage data innovation in life sciences. Chapter Markers: [01:33] Joseph gives us a brief introduction to his career and how he got to the position that he has today.  [03:39] Ross asks Joseph about QIAGEN and how OmicSoft complements the existing range of products the company already provides.  [05:09] Joseph talks about the work that is going into their NGS datasets and how the company is extracting value from those datasets.  [06:09] Ross asks Joseph about the types of customers that use this solution.  [13:06] Joseph clarifies where the data underlying OmicSoft comes from. [19:29] Ross asks Joseph how the company approaches educating the customer. [22:44] Joseph explains the decision-making process that companies go through when deciding to either build or buy. [27:15] Ross asks Joseph about the biggest challenges or criticisms people have about the platform.  [31:07] Joseph explains how his biology background has shaped his view of the challenges he faces in his role in product management. [34:11] Joseph tells us where we can find out more about OmicSoft and QIAGEN. --- Download our latest white paper on “Using Machine Learning to Implement Mid-Manufacture Quality Control in the Biotech Sector.” Visit this link: https://connect.corrdyn.com/biotech-ml

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Philipp Vetter über Hoffnung aus China, Fusions-Fantasien in der Pharma-Branche und einen Staats-Verkauf bei DHL. Außerdem geht es um Morphosys, Qiagen, Bayer, Evotec, Infineon, Walt Disney, Fox, Warner Bros. Discovery, FMC Corp., Adobe, AMD, Mercadolibre, Synopsis, DocuSign, Renk, Volkswagen, Auto1, Porsche AG, Schott Pharma, Hensoldt, Mercedes-Benz, BMW, Stellantis, Inditex, Hermès, Beiersdorf, Xtrackers MSCI World Consumer Discretionary (WKN: A113FH), Vanguard USD Corp. 1-3 Year Bond Acc(WKN: A2PCCG) und Xtrackers S&P500 Equal Weight (WKN: A1106A). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Dem DAX gelang es gestern im späten Handel auf ein neues Rekordhoch zu steigen. Kurz vor Handelsende ging es bis auf 17.049 Zähler nach oben für ihn. Das Tagesplus betrug schließlich 0,76 Prozent.

“The history of science, it turns out, is filled with stories of very smart people laughing at good ideas.”—Katalin Karikó Ground Truths podcasts are now available on Apple and Spotify!The list of obstacles that Kati Karikó faced to become a scientist, to make any meaningful discovery, to prevail over certain scientists and administrators who oppressed her, unable to obtain grants, her seminal paper rejected by all of the top-tier journals, demoted and dismissed, but ultimately to be awarded the 2023 Nobel Prize with Drew Weissman, is a story for the ages. We covered them in this conversation, which for me will be unforgettable, and hopefully for you an inspiration.Recorded 30 January 2023, unedited transcript belowEric Topol (00:06):Well, hello, this is Eric Topol with Ground Truths, and I am really thrilled to have with me Kati Kariko, who I think everyone knows won the Nobel Prize with the Drew Weissman in 2023 and she has written a sensational book, it's called Breaking Through. I love that title because it's a play on words, a breakthrough and breaking through, and we have a lot to talk about Kati, so welcome.Katalin Kariko (00:34):Thank you very much for inviting me.Eric Topol (00:36):Yes, well I'd like to start off, as you did in the book with your background in Hungary where of course you started with a tough background in a one room house without running water and you never had exposures to scientists and somehow or other you became interested in science and you attributed some of these things like your biology teacher, Mr. Tóth and the book Stress of Life [by Hans Selye] Could you tell us a little bit more what stimulated you in a career of science?Katalin Kariko (01:18):I have to say that every child is interested in understanding the nature around them and so I was surrounded with nature because we had big garden, we had animals around and it was an exciting thing. The children ask questions and if they try to find an answer and teachers or parents might give the answer, but definitely the school, even elementary school was very stimulating. Teachers, chemistry teacher, figure out how we can make crystals and I was so excited to have my own crystals and things like that and in high school the teachers were so engaging and not like they tried to put all of the information into your brain, but they encourage you to think yourself, so that's all contributed. I think that most of the child in the first, I don't know, six, seven years of their life that's how they can see their parents behaving, their friends, the school, classmates, and they shaped what kind of people they will be at the end and the rest of it is refining.Eric Topol (02:41):Right, right. Well one of the things I loved that you brought up in the book was how much you liked the TV show Columbo. That's one of my favorite TV shows of all time and one more thing, one more thing. Can you talk a little bit about Columbo? Because in some ways you were like the Peter Falk of mRNA in terms of one more thing.Katalin Kariko (03:09):Yes, so I realized that we as researchers, we are not called searchers, we researchers, so we are repeating things. Of course everybody knows who committed the crime in Columbo because this is how it starts and you don't have to figure out, but it seems always that things in a different direction you would lead but all the little clues and some of my colleagues said that they as a physician, they have this tunnel vision. So the patient comes and they can figure out probably from some clues that this is the disease and they get back the lab results and others. Then they realize that one or two things is not fitting, but they always so strongly believe their first instinct. What I taught them to focus on those which will not fit because that will lead to the real perpetrator in case of Columbo.(04:23):And so I like the simplicity. I know that what we are doing this research is very over complicated, but we can break down in very simple question, yes or no and then repeating things and many experiments. When I did one was the experiments really the question and the nine of them was like just controls always. I have to have a control for that, control for that and since I work most of the time with my own hands myself, so I had to make sure that I think through that what will be the experimental outcome and then think about that. Do I have a control for that? So that many times in my brain before I performed the experiment in my brain, I predicted that what will be the outcome, of course you never get the outcome what you expect, but at least you have the control that you can exclude a couple of things and so this is how I function usually in the end of the 20th century, 21st century people did not work like I did alone most of the time.Eric Topol (05:35):No, I see how you described it in the book was just so extraordinary and it really was in keeping with this relentless interrogation and that's what I want to get into is particularly the time when you came to the United States in 1985 and the labs that you worked in predominantly in Philadelphia through that period before leaving Penn to go on to BioNTech. So, you first kind of beached in at Temple University with a monster at least as you portray him in the book. I mean it was nice that he picked you up at the airport, you and your family. How do you say his name? Suhadolnik.Eric Topol (06:31):But not only was the lab kind of infested with cockroaches, but also after working there for a number of years, a few years, you then had gotten an offer to go to Johns Hopkins and when you informed him about that he threatened and did everything he could to ruin your career and get you deported. I mean this was just awful. How did you get through that?Katalin Kariko (06:58):As I mentioned later on, I went back and gave a lecture there and I have to say that I always put positivity in forefront, so I learned a lot from him, and he invited me to America. I was always very grateful, and he was kind, and we did very well, and we did a lot of publication. In one issue of biochemistry, we had three papers and two of them I was the first author, so I worked very hard and so he liked that, and he wanted me to stay there. I just learned that from this Selye book that this is what is given and then what I can do, I cannot change him. I cannot change the situation, how I can get out from it and that's what I focused on, so I am not bitter about him. I liked him and the same for other people. When I get an award, I usually thanks to all of these people who try to make my life miserable. They made me work harder.Eric Topol (08:05):Well, but you were very kind like you said when you went back to Temple many years later to give the lecture because what he did to you, I mean he was so vindictive about you potentially leaving his lab, which he demanded that he be called the boss and he was going to basically, he ruined the Johns Hopkins job. He called them and you were so nice and kind when you went back to give the lecture without saying a negative word about him, so I give you credit, when somebody goes low, you went high, which is nice.Katalin Kariko (08:40):It is important, which I learned from the Selye book, that you don't carry any grudge against anybody because it'll poison you and as Selye also said that when you are very frustrated and very upset, the quickest way you can think about how you can release the stress is revenge. He said, don't do that. It escalate. It hit you back. You have to think about how you can be grateful for the same person you were just ready to take some revenge and that's what you have to practice. Sometimes it is difficult to feel that, but I don't have any bad feeling against my chairman who put my stuff on the hallway.Eric Topol (09:24):Oh yeah, I was going to get to that. So then after a short stint at the Uniformed University of Health Science where you had to drive three hours from Philadelphia to go there and you would sleep on the floor. I mean, I have to say Kati, if I was driving three hours, all I'd be thinking about is how desperate situation I was put in by the prior PI you work with. Any rate, you work there and then finally you got a job with my friend Elliot Barnathan, a cardiologist at University of Pennsylvania. So here you are, you're very interested in mRNA and you hook up with Elliot who's interested in plasminogen activators, and you work in his lab and it's quite a story where one of the students in his lab, David Langer, ratted on you for being blunt about the experiments getting screwed up and then later you wind up working in his lab. Tell me a bit about the times with Elliot because he's a very gracious, I think he was very supportive of your efforts and you got him stimulated about the potential for mRNA, it seems like.Katalin Kariko (10:41):Yes, so I was desperate to be away from my family at Bethesda and try to get back and every day I sent out several applications. This was in 1989, so you had to send letters and then I called up usually the secretaries about what's going on and I called up also a secretary and she said that they were advertised because nobody was good enough. I said, can you ask him to look at again my application? Then half an hour later, Elliot called me back that come and bring your notebook. He wanted to know what kind of experiment I am doing, and he opened when I came a couple of days later and pulled up a northern blot and he said, you have done that? I said, yes, I did. He said, okay, you are hired and so that, because Elliot is just a couple of days younger than me, I convinced him that we should do kind of mRNA research and he agreed, and we did several experiments and he helped me to get all of these experiments ongoing and so it was a very exciting time and I listened. Elliot was there in many awards ceremony including the Nobel Prize. He was my guest because I was very grateful to him because I have to say that he tried to protect me and he get trouble for that because in higher up and when he was looking for tenure, somehow he get R01, several of them, but they did not put him tenure because he was standing up for me and he paid the price.Eric Topol (12:42):Do you think the reason in part that he went to Centocor, a biotech company who I worked with quite extensively was because he stood up for you?Katalin Kariko (12:54):He mentioned to the chairman that he's waiting for whether he will be tenured because he has a job offer with ReoPro what he was doing there in the lab and testing out and the chairman told him that, take that job.Eric Topol (13:11):Yeah. Well, that's interesting. I know Judy Swain very well, and she did everything she could to hurt your career. She demoted you, or actually she wanted you to leave, but you wound up taking a demotion and also Bill Kelley, who I know well, he was the Dean and CEO of the UPenn. Did he ever get any direct involvement with, because much later on he was advocating for your recognition, but during that time, he could have told Judy Swain to stop this, but did he ever get involved, do you know?Katalin Kariko (13:45):I was very low level of nobody, so he would not. It was interesting, we were hired on the same day in 1989. I was first, and I met him, Bill Kelley when the new faculty was hired, and I was so happy because my first project in Hungary was Lesch-Nyhan syndrome, and I know that he discovered the gene, and I was looking up to him very much always.Eric Topol (14:15):Well, you said in the book you were over the moon and I have to say, I worked with him. My first job was at University of Michigan, and I worked with him for six years before he left to go to Penn, and we've been friends all these years, but what happened with Judy Swain, as I read in the book, I got all it bristled. I really was upset to read about that. Anyway, somehow you stayed on, Elliot moved, by the way, during that time with Elliot, you were able to get mRNA to make urokinase plasminogen activator (uPA), and that was a step in the right direction. Before we leave, Elliot, if you had stayed there, if he had gotten tenure, do you think you would've ultimately together made the discovery that you did with Drew Weissman?Katalin Kariko (15:05):I couldn't be tenured because it is a clinical department and I had a PhD and nobody at the clinical department can be, but I could have been research associate professor if I can get a grant and in 1993, I already had submitted grant on circular RNA. When people in these days, they say that, oh, that's a novelty. Oh, in 1994, 1995, I had several grants on circular RNA I submitted for therapeutic purposes, and Elliot helped me with English and computer, everything what he could, but it is important that he was not an immunologist and I needed discovery. When I work with him, I did not realize the mRNA was inflammatory.Eric Topol (16:02):Right, right, exactly. We're going to get to that in a minute. Now, after Elliot left, then you needed someone else to support you, and you wound up with, as I mentioned earlier, David Langer, a neurosurgeon who you previously knew, and he also stood up for you, right?Katalin Kariko (16:18):Yes, yes. So at the beginning, every lab, when you have a medical student, they kind of know everything. One day he just told me that, Kati, I will want to learn everything you know, and I will know everything you know. I said, oh, by that time while you are learning, I learned so much more, you never catch me. That always I had to put him back, but kind of he liked how I worked, I concentrate, I didn't chitchat. Then he was just keep coming back when I was working, even with Elliot and he advanced from medical student to residency and so on, and then when he learned that I have no job because Elliot is leaving, then he went to a Eugene Flamm, the chairman of neurosurgery, and he convinced him that neurosurgery needs molecular biologics. That's what he was arguing and thanks to David and the chairman Eugene Flamm, then for 17 years I had a laboratory, and I had a financial support. Not much.Eric Topol (17:36):Yeah, I mean that was great, but again, you were not getting any real support from the university and then all of a sudden you show up one day and Sean has all your lab, everything that you worked on thrown in the hallway. I mean, that's just incredible story, right? At any rate, you then wound up because you were basically hawking mRNA as a path of science. It's going to be important. By the way, my favorite quote in the book, Kati. The history of science it turns out is filled with stories of very smart people laughing at good ideas. I just love that quote and it kind of exemplifies your career and your success, but you were steadfast and you ran in, of course, the famous story to Drew Weissman at the Xerox machine, and you were hawking trying to get anybody to believe it as you called it, led to the mRNA Believers Club, which only a handful of people in the world ever got there.(18:38):And here you have you take on something that obviously 1960 in your lifetime, early in your lifetime it was discovered, but everyone knew it was unstable, very difficult to work with, very challenging. Of course, you realized that could be beneficial, but you hooked up with Drew the immunologist that you mentioned, and I didn't know by the way, he had type one diabetes. I learned that from your book, and both of you worked so hard and it's just really incredible, but while you're at Penn, the famous or infamous Jesse Gelsinger case and his death occurred and he had the cytokine release syndrome, and you learned from that, right?Katalin Kariko (19:25):Yes. By that time, we also could see that the RNA could be inflammatory, but in his case, of course, because the virus was causing it or what certain condition caused that. I have to say that, people work at gene therapy at Penn and mostly of viral programs. When I mentioned I tried to make gene therapy with mRNA, of course everybody felt sorry for me. Poor Kati, hate RNA, it always degrade, but I have to say the degradation is coming mostly because the molecular biology laboratory, they use plasmid, and when they isolate plasmid, like the QIAGEN kit, they start with the RNAs. They add RNAs because you have to eliminate the bacterial RNA, and they contaminate the whole laboratory, the refrigerator door, the gel opera, everybody's RNAs and so that's what extra problem with working with RNA. So I could make RNA, and so it was working and kind of try to express that and I made a lot of RNA for people probably they still have in their freezer, never tested because I was a pusher.Eric Topol (20:52):Yeah, yeah. Well, what was fascinating of course is you had already learned in mice about this inflammation from putting mRNA in vivo, and then you made the remarkable discovery, which was the paper in Immunity that had been rejected by Nature and many other papers, even though you had been told if you could get a paper in Nature, maybe that could help your career, right. Back in 2021, the journal of Immunity, a very highly regarded self pressed journal, they asked me to comment on your discovery and I wrote, you may have seen it. Of course, several people wrote Tony Fauci and others. What I wrote was what began as a replacement for a uridine base to squash an inflammatory response in mice evolved into the basis for a broad therapeutic platform to fight both communicable and non-communicable diseases in people. So, this discovery that you made in that classic 2005 paper, which is the most important paper ever published in the journal Immunity, was the Toll-like receptor was mediating the inflammation.(22:05):And if you change the uridine to pseudouridine, you could essentially blunt or block the inflammation. This was a seminal discovery that opened up mRNA, but not just for Covid of course, but for so many pathogens and as we'll talk about when we wrap up about all these other things. So when you did this paper and Drew said when it's published, the phones are going to be ring off the hook and no one even acknowledged the paper, right? I mean no one realized how this was one of the most important discoveries in the history of biomedicine, right?Katalin Kariko (22:43):Yes. Especially knowing that Drew is not the person who is exaggerating things. Drew is very modest and would not say such things. I am more like daughter, maybe this happened, but he is not like that and I got the one invitation to go to the Rockefeller University for a meeting, and then I went to Japan from 2005 and it was 2006. Both of them that was invitation, and nothing happened in 2007, 2008 and 2009.Eric Topol (23:24):But those meetings that you went to, they were kind of obscure like microcosm groups. I mean they were relevant to your work, but they didn't realize this is a big deal. I mean, this is like a world changing type of finding because now you could deliver things in cells. Now of course, you worked on this for three decades and the people that think that you can do a flash in the pan science, but at the same time nanoparticles separately were being pursued. How important were the nanoparticles to make for the package for the ultimate success? When Covid hit in late 2019 and now you had been working at BioNTech, how would you rate the importance of the nanoparticles in the story?Katalin Kariko (24:23):For the vaccine it definitely is important because everybody ask the mRNA, if not immunogenic, where do you have the adjuvant? Where is the adjuvant? Then lipid nanoparticle contains an ionizable lipid, which was the adjuvant and why it is important that not the mRNA was inducing the response because the mRNA induced interferon, and if you have interferon, then follicular T-helper cells is not form, and then you get very low amount of antibodies, but if you do not induce interferon, but you induce IS6 and other cytokines is beneficial to have high level of antibodies, so that's what the ionizable lipid was causing and that's the adjuvant in the lipid nanoparticle. Yes, I always emphasize that it is very important and of course when we use the particle that was totalization, then it did not contain ionizable lipid.Eric Topol (25:24):Right? I think that's where there's a misconception because of the Nobel Prize recognition last year, a lot of people think, well, that's all tied only to the Covid vaccine. Actually no, your discovery was much bigger than that and it was applied for the Covid vaccine of course with the nanoparticle package, but yours is as we'll get to in a moment, much, much bigger. You left Penn, that was in 2013, and then you spent several years in Mainz, Germany working with the folks at BioNTech, and you really enjoyed that and they appreciated you then as opposed to what you dealt with at Penn where it was just that you kept hearing about the dollars per net square footage and all these ridiculous things and just extraordinary to go back there. Now I just want to mention about your own gene transfer, your daughter. Your daughter is a two-time gold medal Olympiad in rowing, which is incredible. So she didn't go down the path of science, but she also became a world leader in a field. Is that transmitted on a particular chromosome in the family?Katalin Kariko (26:54):I think that she just could see that you have to focus on something and then you give up many things and you focus and then achieve, and then you get the new goal, set up a new goal. I mean she get somewhat articulated at Penn, she get a master in science and later in UCLA, she get a MBA degree, but 10 years she was like, for me, it is a very boring thing, just rowing going backwards. Isn't that boring every day? She said, no, mom, it is fun. Every practice is different, I enjoy. The minute I don't enjoy, I will stop doing it.Eric Topol (27:36):Yeah. Well it's amazing story about Susan and of course the expansion of your family with a grandchild and everything else that you wrote about in the book. So now let's go to this story, the big story here, which is mRNA. Now you can get into cells, you can deliver just about anything. So now it can be used for genome editing, it can be used for all these different pathogens as vaccines and including not just pathogens but potentially obviously cancer, to rev up the immune system, neurodegenerative disease to prevent these processes and potentially even preventing cancer in a few years ahead. How do you see this platform evolving in the years ahead? You already have seen many vaccines getting approval or under intense study for pathogens, but that just seems like the beginning, right?Katalin Kariko (28:38):Yes, yes. When I came to Penn, the major advantage was going to lectures and when I went to the lectures, I always at the end of it think, mRNA would be good for it. So, I was collecting all of these different fields and then what happens is right now I can see the companies are making those RNA, which I thought that it will be useful and even many, many more things that they are applying and now it is up to those specialists to figure out they don't need me. They need experts on cardiology and other fields and allergies. There is also to tolerate allergies and there are so many fields scientists will be figuring out there what is useful for the mRNA, and they can just order now or create their own RNA and test it out.Eric Topol (29:38):It's actually pretty amazing because I don't know where we'd be right now if you had not been pushing this against all adversity. I mean just being suppressed and being told, put your stuff out in the hallway or being thrown out of the university and not being able to get any grants, which is amazing throughout all this time, not being able to get grants, it tells a big story and that's why the book is so sensational because it's obviously your autobiography, but it tells a story that is so important. It goes back to that memorable quote that I mentioned. You wrap up the book with your message of your life story, and I do want to read a bit of that and then get your reaction. My first message is this, we can do better. I believe we can improve how science has done at academic research institutions.(30:38):For one thing, we might create a clearer distinction between markers of prestige, titles, publication records, number of citations, grant funding, committee appointments, etiquette, dollars per net square footage, and those of quality science. Too often we conflate the two as if there's one in the same, but a person isn't a better scientist because she publishes more or first perhaps, she's holding back from publication because she wants to be absolutely certain of her data. Similarly, the number of citations might have little to do with the value of the paper and more to do with external events. When Drew and I published our landmark Immunity paper and indeed it was, it barely got any notice. It took a pandemic for the world to understand what we've done and why it mattered. I mean, that's profound, Kati, profound.Katalin Kariko (31:42):I have to tell you that what I could see as the science progress. Every scientist starts with understanding something to help the world but somehow they publish because they have something to say, but somehow, it's shifted. Now we want more money, more people would come, those people had to get publication because otherwise they cannot graduate. They need first to author a paper. They publish even when it is not finished or have nothing to say and then somehow the focus is promotion. You are advancing your position, and the tool is doing the experiments. If you see I was demoted, I was pushed out so if my goal would have been to see that I am advancing, then I would give up because that's what the problem is. So that focus is going away from the original thing that we want to understand the science because if you want to understand the science, you are even happy when you can see a publication doing half of that you have done already because you say, I wanted to understand, here's a paper they did, similar thing I did, but the people think, oh my god, my journal paper is out and my promotion is out because they discovered and they published before me, so that's the problem.Eric Topol (33:12):Well, I mean if I made a list of all the adversity that you faced from growing up in the Russian communist run Hungary to coming to the US not even knowing the language and also all the sacrifices you made along the way with your family and when you would go to Bethesda or when you moved to Mainz or I mean all along the whole time, no less what the university of Temple or Penn. I mean the list is very long and somehow you prevailed above all that, which is just so startling but another thing I want to just get into briefly, as you know, this has been a shocking counter movement to the vaccines and giving ridiculously the mRNA as a bad name. In the book, you kind of had a way to foreshadow this because back in the 1968 pandemic that you obviously experienced, here you talked about that.(34:30):You said we restricted our movement, limiting our contact with others. We scrubbed, we disinfected. I suppose the party encouraged this, but nobody complained about government overreach. This was a virus. It had no ideology, no political agenda. If we weren't careful, it would spread, then we would all suffer. These were just the facts. That's how viruses work. So how come we still don't know that? That was 1968 in Hungary and here we're go in the United States, and we have a huge movement, anti-vaccine, anti mRNA, Covid vaccines, and it's very worrisome because all the great science is threatened by this misinformation and disinformation. What are your thoughts about that?Katalin Kariko (35:27):Yes, I heard that viruses, they love democrats because everybody can do whatever they want, whereas in other countries give an order, everybody has to have vaccine and then that's different, but yes, I understand that the novelty the people were always against, even when X-ray was introduced, people thought that people will look through my clothes and seeing me naked because they take part of the truth and they don't say, maybe through the flesh is going through and I can see somebody's bone or something. Then they distort, and they create a fear and if you make fear, then you can control like Lord of the Flies, somebody you are afraid of and then you can control and you can be afraid of the virus or you can be afraid of the vaccine. Then that's what I don't understand exactly true said that when they investigated those who are spreading most of these news about against the vaccine is they are selling some kind of products benefiting just like a hundred years ago, those who were afraid that they can see through their clothes some they start to sell X-ray resistant underwear.(36:57):Of course people, they made money on the people's fear. I don't know that's how to fight it or I think that the honesty when the scientists would say that, listen, we don't know today how it spread. This is how we suggest, be afraid, wash everything. Oh no, we know that it is in the air so that okay, you don't have to wash your clothes when you go out and come back but don't go to crowded places. In politics it's not working because it is like wishy-washy. Yesterday you said something and today, because we learn, they have to understand this is a science process constantly correcting. In politician, I know everything, this is how to do, they want to reflect this confidence. That's what it is and that's why politics everywhere mixed up with this. Some leaders want to reflect this confidence and they do things which helps the virus to spread.Eric Topol (38:11):Right. Well, I'm glad to get your perspective because obviously when you work so hard throughout your career and then you see the backlash, that's unwarranted. It's always good to be circumspect of course, but to say that this was done in a flash in the pan and it's never really, it's gene therapy and it's changing your DNA, I mean it's a lot of crazy things that of course that you brought out in the book as well. Now before wrapping up, you wrote the book before you were awarded the Nobel Prize and this recognition, you and Drew of course became fantastic, so richly deserved, but many things occurred and I wanted to ask you. For example, you did your PhD and your postdoc at the University of Szeged in Hungary, and you went back there, and I think you were celebrated in your university, perhaps the first Nobel laureate. I don't know, I would imagine perhaps. The second, oh okay but also the last thing that was recognized in the book it was a much different thing. It was like the Time 100 recognition but now that you have had many of these unanticipated awards, what are your thoughts about that? I mean, it is wonderful to get recognized by the university that you trained and the people that you grew up with.(39:53):Has this changed your life or is it really very much the same as it was?Katalin Kariko (40:00):My life is very much the same as it was. I am living in the same house. We moved in 1989 and okay, last year I get a new car. Up until then, I never had, only just some beat-up, last year I purchased my first new car but that's luxury when you are 68 years old, you could afford. Everything was a surprise because 40 years I never get any award and the first award I get in 2021. I tried to articulate to more people, life as a scientist is similar to mine. They are immigrant, they are not recognized and I try to tell them just not to focus something like the university is not grateful. Who is the university? Just they are walls. What administrator would tap your shoulder. You have to know that what you are doing is important and if you get pushed around, you always have to do what Selye said, figure out what you can do. Always that, not what they should do. The agency should give me the money, the boss, the superior should help me. No, I cannot make other people to do. I have to figure out what I can do. I can write better and better and rewrite, generate more data for a submitted grant application and always, that's why all of these naysayers made me better because I'm not focused on revenge or anger, but always, how can I be better.Eric Topol (41:53):So that gets me to what you do next. I know you're an avid reader. I know you read so much about science and your field and broader of course I take it you still are doing that, but what's in the next chapter for you? I can't imagine you're ever going to rest.Katalin Kariko (42:16):No, no. I will be six feet under when I can rest, I realize now. It is just that you are on a different field, and you understand like nucleotides, how naturally you make RNA, what is the transporters, what is happening in the mitochondria, different things that iron sulfur clusters and then you start to investigate like three months I was just reading one topic. I didn't even know about it or how in my life I was reading so many things. I realized there are so many diseases, I understand what is the reason, people don't. When I was at Penn I went to different people, professors about my idea for certain diseases but I was nobody and nobody listened. Now, I'm somebody. I have to be very careful because I say a name of the disease people will line up here and say, don't talk to Eric. Go and do something, help us and so that's what I try to help. I think that I understand certain disease, which is so enigmatic and nobody has a clue and maybe I have a solution for that. That's what I try to do now.Eric Topol (43:38):Do you ever go to Penn? Do you ever go to work in there?Katalin Kariko (43:44):No, I don't. When you are forced to retire, and I knew that they would throw me out because it was 2012, right before Christmas I was told that get out because you didn't get the 2012. Last time I submitted an mRNA for stroke therapy. Still very valid and good idea but anyway, I knew that I will be pushed out, but I don't have grudge, even the chairman. How can I expect the neurosurgeon who is doing the operation he just can see that I did not get the funding and those people who make the decision that my proposal is not good, they are expert. He's not an expert. He just can see that this is what the expert said. I talk to him, I don't blame anything.Eric Topol (44:37):Good for you. I mean I think it's much easier to be vindictive and you have to have the philosophy that you have, which is not to hold any grudges after all that has basically been done to you by many people along the way and I think we've covered that. I know this is a very different interview perhaps than many others that you've had. I didn't bring up the teddy bear and I didn't bring up a lot of things that others have brought up because they've already been covered. I wanted to get into what you had to endure, what you had to do to persevere and how it has changed the life science and medicine forever and now, still today, the mRNA package will be improved. I mean we've already learned, for example, the change of the two proline substitution that Andrew Ward at my place, along with Jason McLellan and others to make it to better immune response. It can be improved with a 6-P proline substitution. We can beat nature just like you did with the uridine substitution and the nanoparticles will improve and this whole package has got an incredible future but it's thanks to you, if it induced massive inflammation, it never would've been possible.Katalin Kariko (46:02):Yes, I always said that hundreds and thousands of scientists, every time I thanks them, those people, even not with us, I was reading their papers and it all contributed to this development and learning. So, I am not thinking that I was many, many other people together, we did that.Eric Topol (46:30):Well, I am so indebted to you as everyone who understands sciences, and it's of course a bigger story than mRNA. It's what you endured and how you persevered and against all odds, I mean truly against all odds, so thank you. Did I miss anything that I should have asked you about?Katalin Kariko (46:51):No. I have to say the book came out and now I can see in different social media that how other scientists get inspired. There was one who said that she quit doing PhD and she read my book and she cried, she laughed, and she went back. She realized that there is more to it because so many is expecting to do some work and then there will be some rewards. The rewards is this is not a short distance. This is a marathon to be scientist and you have to see the goals and it will one day and you might not the one that cross first the finish line, but you are helping others. That's what is important and that's what I am glad that I work with this and write this book so that other scientists more can associate because they feel the same way, that they are not appreciated. Things are not going as expected and then they might be inspired not to give up and that's what is also an important message.Eric Topol (48:11):Well, that's why I love the book because it is so inspirational and it will make people cry. It will make people commit to science or appreciate it more than ever. I don't know if you saw it, but I put it as my 10 favorite books for 2023 and indeed, I could have been the most favorite in many respects. So I hope more people listening or watching the video will read the book because it has a lot. I'm so glad you wrote it, Kati, because if we only knew you from papers and Nobel Prize, you wouldn't know the true story. We wouldn't know really what your life has been like over these many decades. So, thank you for that as well and thank you from the life science, the medical community, and for everyone, for all that you've done to change the future and the current state of medicine.Katalin Kariko (49:10):Yeah, thank you very much asking and I might add to the book that the book is published in many different languages is coming Italian and French, German, Thai, Japanese, Chinese. So scientists all over the world can read their native language and maybe they will be inspired.Eric Topol (49:28):Oh, I have no question about that. It's a story that it should be a movie so that the people that won't read the book will hopefully watch the movie. Has there already been a plan for that?Katalin Kariko (49:40):There was, but I don't think that you know they have this strike during the summer, and I don't know where it ends.Eric Topol (49:52):I wouldn't be surprised if it gets done in the future and I hope they'll consult with you, not just read the book and it'll be interesting who they get to play you in the movie, but thank you so much, Kati. What a joy and I look forward to future visits with you. Get full access to Ground Truths at erictopol.substack.com/subscribe

Diese Woche rösten wir mal wieder ein Depot, das Depot von Noah. Er investiert nach der Dividendenstrategie. Dazu wie immer die Themen sowie die Tops und Flops der Woche. Zum Schluss gibt es noch spannende Investmentideen und der Ausblick auf die kommende Woche darf nicht fehlen.

Die Stimmung an den Aktienmärkten hat sich in dieser Woche wieder verschlechtert. Der DAX gab die vergangenen beiden Handelstage ab. Heute geht es zunächst darum, sich über der Marke von 16.400 Punkten zu halten.

In der heutigen Folge von „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über die Rückkehr von FOMO an der Wall Street, eine Hausse bei Biotech und den Bitcoin auf 2-Jahreshoch. Außerdem geht es um Qiagen, Volkswagen Vz., Boeing, Spirit AeroSystems, United Airlines, American Airlines, Airbus, Johnson & Johnson, Merck &. Co., Ambrx Biopharma, Harpoon Therapeutics, Atai Life Sciences, Bitcoin, Schweizerische Nationalbank, Nvidia, AMD, Marvell, Intel, Dell, HP, LG, Samsung Electronics, Mercedes Benz, Mobileye, Apple, Meta. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Nachdem der DAX gestern am Vormittag noch im negativen Bereich notierte, gelang es ihm dann gegen Mittag ins Plus zu drehen. Am Ende des Tages ging er mit einem Zugewinn von 0,74 Prozent aus dem Handel.

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über Turbulenzen bei Boeing, einen Mega-Aktienrückkauf bei Qiagen und was sonst noch wichtig wird in dieser Woche. Außerdem geht es um Nvidia, Alaska Airlines, United Airlines, Catalent, Bitcoin, Invesco Nasdaq Biotech ETF (WKN: A12CCJ), iShares Nasdaq Biotechnology (WKN: A2DWAW), AstraZeneca, Amgen, Sanofi, Gilead, Biogen, Moderna, Biontech, Genmab, Atai Life Science, Global X Genomics & Biotechnology (WKN: A2QRCP), Bristol Meyers-Squib, BB Biotech. Wir freuen uns über Feedback an aaa@welt.de. Ab sofort gibt es noch mehr "Alles auf Aktien" bei WELTplus und Apple Podcasts – inklusive aller Artikel der Hosts und AAA-Newsletter. Hier bei WELT: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über lange Gesichter bei Conti, den Übernahme-Coup einer Schweizer Chemie-Größe, und euphorische GIFs bei Bitcoin. Außerdem geht es um Qiagen, Merck KGaA, Carmot Therapeutics, Spotify, Twilio, Netflix, Meta, Nvidia und Allianz. Wir freuen uns über Feedback an aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

The publication of this podcast was funded by QIAGEN. Tune in to our latest podcast for valuable insights on non-small cell lung cancer (NSCLC). Esteemed contributors to this discussion include Terri Conneran, a Patient Advocate and founder of KRAS Kickers, and Colin Lindsay, a Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie in Manchester, UK. Both experts underscore the pivotal importance of biomarkers, diagnostic technologies, and collaborative efforts in enhancing survivorship. During this episode, you'll hear about the need for early biomarker testing in NSCLC, along with a forward-looking exploration of the field's future. Lindsay offers an overview of the current treatment landscape for NSCLC, shedding light on issues like late diagnosis and targeted therapies, as well as outlining next-generation sequencing and liquid biopsy as tools to enhance NSCLC testing. Patient experiences are explored, with Conneran sharing her personal journey with diagnosis and treatment. Speaker Bios: Terri Conneran – Patient Advocate and Founder of KRAS Kickers, Charlotte, North Carolina. United States. Colin Lindsay - Clinical Senior Lecturer and Honorary Consultant in Thoracic Medical Oncology at The Christie, Manchester

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Laurin Meyer und Nando Sommerfeldt über einen düsteren Ausblick im E-Auto-Markt, klare Sicht bei Jenoptik und Heißhunger bei McDonald's. Außerdem geht es um ON Semiconductor, Tesla, Panasonic, Qiagen, Jenoptik, Microsoft, Meta, Amazon, Alphabet, Schindler, Bachem, Interroll, Pictet Swiss Mid Small Cap (WKN 988389), Swiss Small & Mid Cap Equity (WKN 921843), SaraSelect (WKN: 634756) und Siemens Energy. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Hier findet ihr alle AAA-Bonus-Episoden bei WELT – dazu den AAA-Newsletter und noch weitere WELTplus-Inhalte: https://www.welt.de/podcasts/alles-auf-aktien/plus247399208/Boersen-Podcast-AAA-Bonus-Folgen-Jede-Woche-noch-mehr-Antworten-auf-Eure-Boersen-Fragen.html Hörtipps: Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Außerdem bei WELT: Im werktäglichen Podcast „Kick-off Politik - Das bringt der Tag“ geben wir Ihnen im Gespräch mit WELT-Experten die wichtigsten Hintergrundinformationen zu einem politischen Top-Thema des Tages. Mehr auf welt.de/kickoff und überall, wo es Podcasts gibt. +++ Werbung +++ Du möchtest mehr über unsere Werbepartner erfahren? Hier findest du alle Infos & Rabatte! https://linktr.ee/alles_auf_aktien Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In this week's episode, Qiagen CEO Thierry Bernard gives us a look inside the diagnostics leader both today and a few years ago when it was responded to the world's dire need for diagnostics. Bernard takes us back to the early days of the pandemic, including his perspective on how different countries responded to the crisis. We'll also hear his vision for the future of diagnostics including how Qiagen will make testing even simpler. At the start of the show, Host Tom Salemi and Chris Newmarker, executive editor of life sciences, talk with Senior Editor Danielle Kirsh about the recently released Women in Medtech issue of Medical Design and Outsourcing magazine. Kirsh shares data she's collected on how many women hold senior positions in the medical device industry. We're seeing some progress, but not enough. Thanks for listening to the DeviceTalks Weekly Podcast. Subscribe to the DeviceTalks Podcast Network on any major podcast player.

In long-term care, few infections are potentially more dangerous than tuberculosis. Failing to detect a TB case among residents could prove deadly — but many long-term care providers are still under-testing or relying on outdated methods to check for TB.In this podcast, infection preventionist/CEO IPCWell, Dr. Buffy Lloyd-Krejci discusses key strategies to reduce the risk of active TB in long-term care facilities. Instituting a comprehensive TB prevention program can get workers in the door faster and keep residents safer. You'll learn about best practices for TB screening, CDC testing guidelines and the importance of TB prevention for both staff and residents. For more information, visit qiagen.com/us

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über den Sartorius-Schock, das Merck-Mentekel und einen Lift bei Lilium. Außerdem geht es um Siemens Healthineers, Qiagen, Eckert & Ziegler, Synlab, MTU Aero Engines, Airbus, Intel, AstraZeneca, Allianz Global Artificial Intelligence (WKN: A2DKAU), DWS Artificial Intelligence (WKN: 847414), Amundi MSCI Robotics & AI ESG Screened ETF (WKN: A2JSC9), WisdomTree Artificial Intelligence ETF (WKN: A2N7KX), Xtrackers Artificial Intelligence & Big Data ETF (WKN: A2N6LC), L&G Artificial Intelligence (WKN: A2PM50), Nvidia, Meta, Amazon, Microsoft, Apple, Broadcom, Alphabet, UpStart, C3.AI, Nvidia, Blackberry, Palo Alto, Appian, UiPath, Alteryx, Splunk, Samsara, Autodesk, Pure Storage, Service Now, iShares S&P 500 Swap ETF (WKN: A2QAJB) und Lyxor MSCI All Country World ETF (WKN: LYX00C). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In a session from Future of Field Service Sydney, Sarah talks with Jordan Argiriou, Director, Service Solutions APEC at QIAGEN about how the company is channeling its service focus to navigate current economic conditions.  

US equity futures are indicating a higher open as of 05:00 ET. European equity markets are higher, following a positive performance in Asia. Risk appetite remains buoyant on the back of Friday's NFP report, aided also by China's reopening, which may be keeping recession concerns suppressed. In M&A news, the focus is on the pharma/medical sector.Companies Mentioned: Salesforce, AstraZeneca, CinCor, Amryt, Ipsen, Albireo, Qiagen, Alibaba

Ranked #2 in the World! Authored over 8 Books! Over 25 years of experience! Worked with over 1000 brands in 36 countries! My next guest Dr. Jerome Joseph has the winning formula to help you with your personal brand!Jerome Joseph, CSP s' experience as CEO a publicly listed Brand Agency, has led him to work with some of the biggest Global Brands. including Dell, Standard Chartered, Pfizer, BASF, and many more). He is an award-winning global speaker on Branding and in 2018, was recognized as one of the TOP 30 GLOBAL GURUS worldwide for Branding. He is the only Asian based in Asia on the list. He was ranked No. 2 as a Global Brand Thought Leader in 2020Dr. Joseph talks about creating strategic communications with certainty to drive the customer experience. He builds his brand message on four key pillars of Clarity, Credibility, Consistency, and Connection!   He has a clear focus on storytelling that ties in key points to involve his audience with high emotion to build brand trust.Dr. Jerome Joseph is a brand experience strategist, brand coach, and best-selling author. His experience with world-acclaimed brands has led him to become one of the early pioneers of internal branding – an employee and company culture-focused approach to branding as well as driving brand across people, customers, and organizations. With more than twenty years of branding experience under his belt, Jerome is a master in innovative brand differentiation and creating extraordinary branded experiences. Jerome runs programs and keynotes ranging from Internal Branding (Building Brand Champions in your organization), Brand Mastery (Strategies to Build a World Class Brand), Branded Customer Experience, Personal Branding, and Asian Brand Strategies based on Lessons from the top 30 Asian Brands.Dr. Jerome has impacted more than 1000 brands in over 36 countries, such as Pfizer, Dell, BASF, SENAAT, Prudential, AIA, Singapore Sports Council, QIAGEN, SAP, Asia Pacific Breweries, Singtel, Master Builder Solutions, Petronas, Honeywell, DBS and many more.His cutting-edge thinking, solid case studies, and systematic approach to brand building have enthralled audiences all around the world, making each of his programs a truly memorable one. His love for story-telling and talent for distilling experiences into succinct, bite-sized lessons has garnered rave reviews from clients.Dr. Jerome holds the Certified Speaking Professional (CSP) designation, which is held by the top 12% of speakers in the world as an award for speaking expertise. He was awarded the prestigious Global Speaking Fellow in 2015 as the 2nd Singaporean to earn this award and the 30th speaker in the world to achieve this. Currently, less than 1% of speakers globally hold this designation. He also holds the Practicing Management Consultant (PMC) designation awarded to experienced industry veterans in consulting.Let us Welcome Dr. Jerome Joseph to the Follow The Brand Podcast, Where we are Building a 5 STAR Brand That You Can Follow!

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Nando Sommerfeldt über das Kunststück von Goldman Sachs, die Rezession der Superreichen und die beliebtesten Aktien der Deutschen – von denen sie gar nichts wissen. Außerdem geht es um Johnson&Johnson, Roche, Lockheed Martin, Thermo Fisher, Qiagen, Tesla, Amazon, Beyond Meat, Danaher, Microsoft, UnitedHealth, O-I-Glass, Starbucks, McDonalds, Nestlé, Tesla, Mercedes, Volkswagen, Apple, Deutsche Telekom, Biontech, WisdomTree BioRevolution ETF(WKN: A3CY21), iShares Healthcare Innovation ETF (WKN: A2ANH2), Pictet-Water Fonds (WKN: 933349), Pictet - Global Megatrend Selection (WKN: A0X8JZ), RobecoSAM Sustainable Water (WKN: A2QBUQ), AXA WF Robotech (WKN: A2DJG8), Credit Suisse JPMorgan Sustainable Nutrition Fund (WKN: CS0028), Allianz Global Water (WKN: A2JRGT) und Van Eck Sustainable Future of Food (WKN: A3DP9K). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Nando Sommerfeldt über einen gefeierten Biogas-Deal, die Kursgewinne des Xi und bereiten Euch auf das Jahrzehnt der Hochinflation vor. Außerdem geht es um Bank of America, Bank of New York Mellon, Archaea Energy, News Corp, Fox Corp, JD.com, Alibaba, Lufthansa, Qiagen, Bio-Rad Laboratories, Roche, Siemens Healthineers, Abbott, Thermo Fisher, Sartorius, SAP, Fresenius Medical Care, Zoetis und Pfizer. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Daniel Eckert und Holger Zschäpitz über eine kalte Dusche der Bank of England, gute Zahlen von LVMH und schlechte Nachrichten für Uber-Aktionäre. Außerdem geht es um Lyft, Puma, Qiagen, Zalando, AboutYou, Global Fashion Group, Fashionette, Social Chain AG, Siemens, Home24, Mister Spex und Fielmann. Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

In der heutigen Folge „Alles auf Aktien“ sprechen die Finanzjournalisten Anja Ettel und Holger Zschäpitz über neue Zinserhöhungsängste, die nächste Runde im Twitter-Tesla-Duell und eine Milliardennachfrage nach Porsche. Außerdem geht es um Infineon, Qiagen, Siemens Energy, Zalando, Deutsche Bank, Tesla, Twitter, Vertex Pharmaceuticals, Porsche, Hypoport, Helma Eigenbau, Vonovia, LEG, TAG Immobilien, Verbund, EVN AG, iShares Developed Markets Property Yield (WKN: A0LEW8), iShares Immobilien-ETF thesaurierend (WKN: A2JKTX), VanEck Global Real Estate (WKN: A1T6SY), Amundi FTSE EPRA NAREIT Global (WKN: A2H9Q1), WisdomTree New Economy Real Estate (WKN: A3C6JU​). Wir freuen uns an Feedback über aaa@welt.de. Disclaimer: Die im Podcast besprochenen Aktien und Fonds stellen keine spezifischen Kauf- oder Anlage-Empfehlungen dar. Die Moderatoren und der Verlag haften nicht für etwaige Verluste, die aufgrund der Umsetzung der Gedanken oder Ideen entstehen. Für alle, die noch mehr wissen wollen: Holger Zschäpitz können Sie jede Woche im Finanz- und Wirtschaftspodcast "Deffner&Zschäpitz" hören. Impressum: https://www.welt.de/services/article7893735/Impressum.html Datenschutz: https://www.welt.de/services/article157550705/Datenschutzerklaerung-WELT-DIGITAL.html

Host Dr. John Sweetenham, of the UT Southwestern's Harold C. Simmons Comprehensive Cancer Center, and Dr. Bridgette Thom, of the Memorial Sloan Kettering Cancer Center, discuss a novel intervention to address financial toxicity and social need using the Electronic Medical Record.   TRANSCRIPT Dr. John Sweetenham: Hello. I'm Dr. John Sweetenham, the associate director for clinical affairs at UT Southwestern Harold C. Simmons Comprehensive Cancer Center and host of the ASCO Daily News podcast. My guest today is Dr. Bridgette Thom, a researcher at Memorial Sloan Kettering (MSK) Cancer Center. We'll be discussing a novel approach to address financial toxicity that uses the electronic medical record to streamline referrals to financial assistance and counseling for high-risk patients. Our full disclosures are available in the show notes, and disclosures of all guests on the podcast can be found on our transcripts at asco.org/podcasts. Dr. Thom, it's great to have you on the podcast today. Dr. Bridgette Thom: Thanks so much for having me. Dr. John Sweetenham: Dr. Thom, the high costs of cancer care have caused major financial distress for many patients and their families. And this, of course, has been the subject of a great deal of literature in recent years. As you noted in your poster presentation at the recent ASCO Annual Meeting, there are limited interventions, despite a need for patient level and system-based solutions (Abstract 6596). Listeners to our podcast will remember a previous discussion that we had with Dr. Derek Raghavan from the Levine Cancer Institute, where they had instituted financial toxicity grand rounds to partially address this problem. Can you tell us about the novel approach that you and your colleagues explored using the electronic medical record to streamline referrals for financial assistance and counseling? Dr. Bridgette Thom: I first have to credit our team for this work. Dr. Emeline Aviki, who is a gynecological surgical oncologist with keen interest in affordability and payment models, founded the MSK affordability working group several years ago. The first priority of the group was to determine the scope of financial hardship at our institution. At the time, we were absent a systematic screening process. So she, our data analysts, and representatives from our Patient Financial Services Program, developed proxy measures to figure out which patients might be having financial issues. Looking through the medical record, we found those patients who had used one of our Patient Financial Services assistance programs, those who had billing issues, and those who had been referred specifically to social work for a financial issue. And in doing so, we found out that about 25% of our patients over a 2-year period were facing some sort of financial issue. Looking closer at that data, patients experiencing financial hardship weren't necessarily being connected to the resources that we had available, which include copay assistance programs, financial assistance programs, and support for non-medical essential needs. So, for example, we had about 1 in 6 patients who had some sort of payment issue, but only about 20% of them had applied for financial assistance. And we wanted to figure out why this was happening and review the process. In doing so, we discovered that too much burden was being placed on already burdened social workers who had to triage all those issues. So Dr. Aviki in her wisdom realized that care providers, physicians, advanced practice providers (APP), nurses needed to make direct referrals to the resources that we had. So we had a place for patients to go, we just needed an easier mechanism for them to get there. And that was the birth of the financial toxicity order set. And she and her team really powered through the developmental and testing phases working with IT, our strategy administration groups, clinical end users, our PFS team, that's Patient Financial Services. We built this order set that allows clinicians directly to refer to our resources. So clinicians, either through their discussions with patients or if patients bring up an issue, through the order set they can select a reason for a referral, the urgency of referral, the clinical location, etc. And then those orders go directly to our Patient Financial Services staff who then contact patients. We piloted this program in late 2020, early 2021 on 1 service, and then used that feedback to roll out the program first to our outpatient clinics and then to inpatient. That process involved a lot of educational efforts, getting the word out, and working with IT and our strategy team to stay on top of the data and monitor referrals over time. Dr. John Sweetenham: Thanks. Could you say just a little bit more about the educational process that you use? I noticed in looking at your poster that the bulk of referrals came either from the clinic nurse or from the APP. Did you tailor your education in any way to the specific provider that was involved? How did you do that piece? Dr. Bridgette Thom: Our affordability working group is an interdisciplinary team and we have nurses, social workers, physicians. So we did a lot of grand rounds work tailored to the audience be it by disease type or clinical role. Dr. John Sweetenham: Great, thank you. This is clearly great work. There's a lot of useful and helpful information in your abstract and in your poster. What would you say are the key takeaways from the intervention? What would you say about the scalability of this approach into community practice as opposed to a very large institution such as yours? Dr. Bridgette Thom: One key takeaway from a process perspective was the need, like I said, for an interdisciplinary approach to handling the issues. That might seem obvious, but it was really crucial to the success of the project to engage key departmental stakeholders and decision makers very early in the process and keep them informed throughout the development of the order set. That definitely helped us to smooth a potentially bumpy road when we're dealing with big systems change. From an outcomes perspective, a key takeaway is the importance of having actionable items to empower the care providers. So while our institution has this amazing program, our Patient Financial Services program which provides counseling, and connects patients to tangible resources, this type of intervention I think could be scalable or applicable to a community practice or smaller hospital, provided there's somebody, a social worker, patient navigator, [or] nurse, that can be a connection for patients and those potential resources that do exist out there. For us going forward, we're going to continue to evaluate the order set, both from the clinical end user and then also the Patient Financial Services staff to learn more about their perspectives and what can be adapted in the order. We also, of course, want to learn from our patients about their experience with the process, and so we have projects, both research and program evaluation, in the works to consider their perspective. Dr. John Sweetenham: Great, thank you. And I guess 1 of the other aspects of this where there is obviously substantial opportunity is that, of course, currently, you're still reliant upon the provider to place the order. And I wonder whether you feel that some form of screening for social need and financial hardship could be embedded within the electronic health record as a key next step, so that you proactively identify those high-risk patients. Dr. Bridgette Thom: Definitely. And that is, in fact, our next step. We are currently piloting our financial hardship screening tool on 4 large services at our institution. The objective here is to, like you said, proactively identify patients who might be at risk and connect them to resources, be it tangible resources, or just counseling or insurance guidance, [and] do that before the hardship can occur. And the goals of our pilot phase are to (1) develop and refine a tool that's both predictive, but also feasible to administer within a busy clinic setting. And then also (2) to work with our interdisciplinary team to adapt the workflow. We can have a great tool, but if we don't have a way to administer it in a clinic, it's not going to do us any good. So for us, that means listening to feedback from, first and foremost, our patients and then the key stakeholders in the process. Our nurses have been integral to this process. We also, of course, our Patient Financial Services, staff, the clinical operations staff, obviously, IT, social work. And once we have these processes figured out and we have our tool solid, we will hopefully expand the screening to all services, and then use data to figure out the optimal screening interviews by disease and treatment type because we feel that this could vary by a patient's treatment trajectory. Dr. John Sweetenham: You note in your poster that additional multilevel interventions are needed to address the problem of financial toxicity at a systems level, and of course, what you have done here is a really great and important step in helping to identify those patients. But identifying those patients who are at particular risk is only beginning of addressing the issue. Could you elaborate a little bit more on other areas that you're exploring in terms of the interventions that you're using? Dr. Bridgette Thom: Sure. And this idea of multi-level interventions comes from my social work training, where there's an emphasis on viewing the individual as being part of a series of dynamic and interconnected relationships and systems: the social ecological theory. So if we think of concentric circles with the patient at the center, there are cascading relationships that are going to impact the course of their care. We radiate out to families and caregivers, a patient's workplace if they're employed, the hospital and the providers there, and then look to bigger systems where a patient lives, their town. If it's in an urban setting or a rural setting, the type of insurance that they have, if it comes from their employer, or if it's a different insurance system, their community and then of course, broader, social, societal, more macro issues. My point and that of many others who work in this space is that we have to consider the context. We can't just build and test interventions that focus on a patient because the patient isn't existing in a bubble. They're existing in relationships with their caregivers, their health care providers, their health care system. And all of that exists in, for lack of a better word, a broken system of structural inequality, systemic racism, and conflicting values about health care as a right. Patient-level interventions are indeed important, but we can't place the burden solely on the patient. And we, as researchers and clinicians in this space, really need solutions that are going to reach across systems. I think, like you said, this project demonstrates that and this is something that I hear from patients in other work that I'm doing. For example, I'm working on a digital intervention to help young adult cancer survivors to build their financial capability and build their understanding of the health care system and insurance systems and financing and all of that. As I co-develop this intervention with patients and survivors, I'm hearing, 'This is great. I'm glad I'm learning these things, but at the same time, my co-pays are unmanageable,' Or, 'I might have to skip my survivorship appointment because I can't afford to take off work that day.' I think we have to really think about, like I said, the context and the bigger picture of the scope of the problem and build and develop interventions that acknowledge that. Dr. John Sweetenham: Well, as you say, very complex, multi-level problem and many interventions needed. But congratulations and kudos to you and your colleagues for addressing one component of this. And we're really looking forward to seeing how this develops and progresses in the coming years. And I'd like to thank you, again, for sharing your insights with us today on the ASCO Daily News podcast and telling us a little bit more about this great work. Dr. Bridgette Thom: Thank you so much for having me. I want to just acknowledge all of the work of our team. It has really been a team effort. We're looking forward to our next steps. Dr. John Sweetenham: And thank you to our listeners for joining us today. You'll find links to the poster discussed today on the transcript of this episode. Finally, if you value the insights that you hear on the ASCO Daily News podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. You can hear more about the MSK Affordability Working Group's efforts on the podcast, Cancer Straight Talk from MSK.   Disclosures: Dr. John Sweetenham: Consulting or Advisory Role: EMA Wellness Dr. Bridgette Thom: Stock and Other Ownership Interests (Immediate Family Member): Caladrius Biosciences, Mediwound, Sierra Oncology, Lipocine, MEI Pharma, Oncternal Therapeutics, Avadel Pharmaceuticals, Chimerix, Avidity Biosciences, Sutro Biopharma, Adma Pharma, Concert Pharmaceuticals, Processa Pharmaceuticals, Curis           An, IMV, Arcus Biosciences, Iovance Biotherapeutics, Qiagen, Revance Therapeutics, DermTech, Zimmer BioMet, Axonics Modulation, Halozyme, Autolus, Pavmed Inc       , Mereo BioPharma, and AADi Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.